Patients with moderate to severe ulcerative colitis are more likely to achieve clinical remission and a range of other outcomes on ustekinumab than placebo, according to the results of a phase 3 trial.

In the pharma-company funded trial (known as UNIFI), 961 patients from 244 international sites were randomised to one of two different intravenous doses of a single, induction infusion of the drug or IV placebo.